Petter B.
- Country
- Norway
- Department
- Oncology
Research Overview
- Single-dose melflufen pharmacokinetics and tumor effects in patients with recurrent glioblastoma undergoing surgical resection
- Phase III Evaluation of Lomustine and Temozolomide Versus Temozolomide in MGMT Promoter Methylated Glioblastoma with or without Tumor Treating Fields
- Phase III Randomized Study of Lomustine With or Without Reirradiation in First Progression of Glioblastoma
Data & Insights
Has run more than one trial at 40 of 109 partner sites.
Specializations
Primary Brain Tumors
This investigator specializes in treating advanced brain malignancies, with particular focus on glioblastoma management across different molecular subtypes, including MGMT methylated and unmethylated variants.
- Newly diagnosed glioblastoma treatments
- Recurrent glioblastoma interventions
- WHO Grade IV gliomas
The investigator explores therapeutic approaches for both initial diagnosis and disease progression scenarios.
Innovative Treatment Combinations
The researcher investigates novel therapeutic combinations integrating chemotherapy agents with established treatments, including exploration of radiation therapy protocols and emerging drug combinations.
- Combined modality treatments
- Alternative chemotherapy protocols
- Targeted therapeutic approaches
Focus includes evaluation of treatment efficacy in various clinical scenarios.
Secondary CNS Conditions
Additional research interests extend to other central nervous system conditions, particularly meningioma and its recurrent presentations, exploring innovative therapeutic interventions including radiopharmaceutical treatments.
- Recurrent meningioma management
- Advanced treatment modalities
- Radio-labeled therapy applications
The investigator evaluates treatment options for patients with limited conventional therapeutic choices.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.